Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017


News SummaryMost relevantAll newsSector newsTweets 

Bayer Stops Sale of Glucose Meter Business

share with twitter share with LinkedIn share with facebook
share via e-mail
01/09/2013 | 12:07pm CEST

By Hendrik Varnholt

FRANKFURT--German pharmaceutical company Bayer AG (>> Bayer AG) will retain its blood glucose meter business, a spokeswoman said Wednesday, confirming a Bloomberg report.

Bayer had put up the unit for sale and had been in talks with French peer Sanofi SA (>> SANOFI) about a deal which could have been valued at around $1.5 billion, people familiar with the matter told Dow Jones Newswires in December.

"We have evaluated several options and decided to retain it," Bayer HealthCare chief Joerg Reinhardt said about the glucose meter business, according to Bloomberg.

Natali Schwab, Eyk Henning and Dana Cimilluca contributed to this story.

Write to Hendrik Varnholt at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bayer AG, SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER AG
10:09a CEO WERNER BAUMANN AT THE ANNUAL STO : “We want to further strengthen Baye..
10:09a BAYER : Annual Stockholders’ Meeting -- Address by Werner Baumann -- Chair..
04/27DJBAYER : First-Quarter Net Profit Up 38% at EUR2.08 Billion -- Update
04/27 BAYER : CFO Dietsch to leave company in May 2018
04/27DJBAYER : First-Quarter Net Profit Up 38% at EUR2.08 Billion
04/25DJBAYER : 1Q 2017 -- Forecast
04/24BAYER AG : quaterly earnings release
04/24 WORLD MALARIA DAY 2017 : -- Bayer partners with Goodbye Malaria to help “E..
04/05DJVECTURA : Bayer Launches New Nebuliser in Poland; Triggers Milestone Payment
04/01 NOT INTENDED FOR U.S. AND UK MEDIA - : -- Phase II Copanlisib Data Show Durable ..
More news
Sector news : Pharmaceuticals - NEC
10:30a REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
07:45aDJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
04/27DJASTRAZENECA : Profit Drops on Decline in Blockbuster-Drug Revenue -- Update
04/27DJASTRAZENECA : Correction to AstraZeneca Profit Drops on Decline in Blockbuster-D..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/27 FDA OKs expanded use of Bayer's cancer med Stivarga to include liver cancer p..
04/27 Bayer A.G. 2017 Q1 - Results - Earnings Call Slides
04/27 Bayer A.G. beats by ?0.16, beats on revenue
04/27 Bayer Q1 top line up 12%; earnings up 38%; cash flow down 36%; guidance raise..
04/26 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2017 Update
Financials (€)
Sales 2017 49 597 M
EBIT 2017 9 987 M
Net income 2017 5 511 M
Debt 2017 11 401 M
Yield 2017 2,53%
P/E ratio 2017 17,53
P/E ratio 2018 16,34
EV / Sales 2017 2,21x
EV / Sales 2018 2,05x
Capitalization 98 162 M
More Financials
Duration : Period :
Bayer AG Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 112 €
Spread / Average Target -0,65%
Consensus details
EPS Revisions
More Estimates Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Human Resources, Technology & Sustainability
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG13.64%106 620
JOHNSON & JOHNSON7.40%335 446
ROCHE HOLDING LTD.10.83%225 921
NOVARTIS AG2.77%203 449
PFIZER INC.4.25%201 641
MERCK & CO., INC.6.30%171 565
More Results